Regulation
Medtronic Hugo Robot Gains FDA Clearance for General Surgery

Key PointsHugo's general-surgery clearance lets hospitals run one robotic platform across common…
View more
- Hugo's general-surgery clearance lets hospitals run one robotic platform across common soft-tissue operations.
- The FDA's AI role stays in postoperative case review rather than directing robotic instruments during surgery.
- General surgery already drives Hugo's fastest procedure growth outside the United States ahead of urology and gynecology.
Medtronic announced on November 17, 2026 that the U.S. Food and Drug Administration had cleared its Hugo robotic-assisted surgery system for general surgery, extending the platform beyond urology into procedures the company estimates account for about 3.5 million U.S. surgeries each year.
The expanded 510(k), a premarket notification route based on substantial equivalence to a legally marketed device, covers all upper-abdominal general surgical procedures. These include cholecystectomy, Roux-en-Y gastric bypass, ventral hernia repair and small-bowel resection. The cleared lower-abdominal procedures are inguinal hernia repair and appendectomy. Medtronic says the combined group represents more than half of all soft-tissue procedures performed annually in the United States.
For hospitals, the decision allows the same robotic platform to be used across a considerably broader range of common operations. Matt Anderson, senior vice president and president of Medtronic’s Surgical business, presented the expansion as a way to give hospitals another option for managing capacity and access while allowing surgical teams to work across care settings.
Modular Hardware and AI-Supported Review
Hugo’s modular design lets teams deploy only the arms needed for an operation and position them for the surgical technique and patient’s anatomy. Its open console is designed to keep the surgeon connected with the operating-room team and patient. The FDA’s documentation for the original system describes software-operated electromechanical arms controlled from the surgeon console, with a system tower and movable arm-cart assemblies as the other principal components.
Surgeons can also use the LigaSure RAS Maryland vessel-sealing instrument with Hugo. Medtronic says the underlying LigaSure technology has been used in more than 45 million open and laparoscopic procedures.
Medtronic’s original U.S. launch announcement describes a Touch Surgery ecosystem connected to Hugo, with preoperative training, remote tele-proctoring and AI-powered postoperative case insights. Surgeons can securely access case videos seconds after a procedure. The ecosystem is not intended to direct surgery or aid diagnosis or treatment, placing the AI role in postoperative review rather than control of the robotic instruments.
The Regulatory Path From Urology
The FDA first cleared Hugo on December 3, 2025 for minimally invasive urologic procedures in adults, with use by trained physicians in an operating-room environment. Medtronic identified prostatectomy, nephrectomy and cystectomy as covered operations and estimated that they account for about 230,000 U.S. surgeries annually.
That urology submission was supported by Expand URO, a prospective, single-arm study of 137 patients at six U.S. investigational sites. The FDA summary says the study met its primary safety and effectiveness endpoints. It evaluated the earlier urology indication, not outcomes in the newly cleared general-surgery procedures.
Medtronic announced on June 3, 2026 that it had submitted separate 510(k) filings for general and gynecologic surgery, with the general-surgery submission including hernia repair. The new clearance turns the general-surgery part of that plan into an expanded U.S. indication.
Adoption and Hospital Use
Medtronic reports a growing U.S. clinical footprint, global Hugo procedure growth at more than twice that of the robotic-surgery market, and a projection that cumulative procedures will surpass 50,000 by the end of its fiscal year. General surgery is already its highest-growth Hugo specialty outside the United States, surpassing urology and gynecology in procedure growth.
Dr. Francesco Bianco, a UI Health surgeon and professor of surgery at the University of Illinois College of Medicine, connected the expansion to treatment choice and surgical education: “Expanding our robotic-assisted surgical capabilities with the Hugo RAS system allows us to offer additional treatment options, while supporting our commitment to advancing surgical education and training the next generation of surgeons.”
The clearance moves Hugo’s U.S. business into the specialty already generating its fastest international procedure growth. Hospitals can now use one platform across a much larger set of common soft-tissue operations, while Medtronic’s commercial opportunity depends on turning that expanded cleared procedural base into regular clinical use.












